Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger RAN-binding domain-containing protein 2 (ZRANB2) is a highly conserved and widely expressed protein containing two RanBP2-type zinc finger domains that specifically recognize RNA motifs (AGGUAA), enabling it to bind pre-mRNA and regulate alternative splicing[1][2][3][4]. ZRANB2 lacks classic RNA recognition motifs but directly influences splice site selection through its unique zinc finger domains[1][2][3]. It acts as an integral component of the supraspliceosome and is essential for the correct splicing of various transcripts, including those relevant to tumor progression and chemoresistance, particularly in breast cancer where it modulates the response to doxorubicin through alternative splicing of genes such as ECT2[4]. Phosphorylation may regulate its activity and subcellular localization, further modulating its effects on splicing[4].
Modulation of alternative splicing (e.g., influencing exon inclusion in response to chemotherapies such as doxorubicin)[4]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger RAN-binding domain-containing protein 2 (ZRANB2).